Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Loop Capital Raises Price Target on AppLovin Corporation (APP) to $385 Following Strong Q3 Results and AI Growth

We recently compiled a list of the 15 AI News That Should Not Be Ignored. In this article, we are going to take a look at where AppLovin Corporation (NASDAQ:APP) stands against the other AI stocks that should not be ignored.

Artificial Intelligence is driving an unprecedented expansion in the potential market size for hardware and software products. According to Bain & Company, the market for AI-related hardware and software will witness annual growth rates of 40% to 55% over the next three years, potentially reaching a valuation between $780 billion and $990 billion by 2027. Companies investing in artificial intelligence know exactly how big of an opportunity this is and are determined not to miss it. Keshav Murugesh, Group CEO of WNS, a global business process management company, talked about its significance at the “CNBC Connect” event in Bangkok. According to Murugesh, many companies are underprepared for AI’s impact, particularly in areas such as government regulation. As such, there is clearly an upside to investing early in the technology.

“Three years from now, if you are investing significantly in generative AI, you might be disappointed, right? As we have seen in many technologies, sometimes the hype is much bigger than the reality. But, three years from now if you are not investing in generative AI, you are going to be terrified. Because those companies that made the investments now, will be far ahead of you”.

– Keshav Murugesh.

READ ALSO: 10 Trending AI Stocks on Latest Analyst Ratings and News and 8 Best Information Technology Services Stocks to Invest in Now

Latest Developments in AI

Let’s look at the latest developments in artificial intelligence to assess how they are helping businesses, customers, and society to reach the next level of success. In its first, Chinese scientists have developed the first AI-powered robot lifeguard to stand watch over the riverside site in Luohe city. Using artificial intelligence, big data, and navigation and tracking technologies, the robot will operate without any human intervention. While it is not the first robot lifeguard, it is the first to be fully automated and needs no intervention, South China Morning Post reported.

In other news, Japanese Prime Minister Shigeru Ishiba has pledged more than $65 billion of fresh support for the nation’s semiconductor and artificial intelligence sector. The move comes in hopes of narrowing the gap between Tokyo and global powers on chip support. Ishiba notes that he wishes to spread positive examples of regional revitalization like TSMC’s chip plant in Kumamoto across the nation.

Speaking of artificial intelligence, it seems that artificial intelligence companies are no longer scaling at the pace they were initially and that the outcomes from scaling up pre-training—the stage in AI model training where large volumes of unlabeled data are used to learn language patterns and structures—have seemingly reached a plateau. To overcome this plateau, researchers are now exploring “test-time compute,” a technique that enhances existing AI models during the so-called “inference” phase, or when the model is being used. This shift has the potential to reshape the AI landscape and impact the demand for hardware, challenging Nvidia’s dominance in training chips as the focus moves to the inference market.

For this article, we selected AI stocks by going through news articles, stock analysis, and press releases. These stocks are also popular among hedge funds.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).

A close-up of a mobile device, showing an advertiser reaching out to a consumer via a software-based platform.

AppLovin Corporation (NASDAQ:APP)

Market Capitalization: $96.12 billion

AppLovin Corporation (NASDAQ:APP) is a technology company that provides end-to-end software and AI solutions for businesses to reach, monetize, and grow their global audiences. The company leverages its AI-powered platform to provide targeted, automated marketing solutions

On November 11, Loop Capital analyst Rob Sanderson raised his price target on AppLovin Corporation (NASDAQ:APP) to $385 from $181 and kept a “Buy” rating on the shares. The rise in price target comes after the company’s Q3 earnings beat and an above-consensus guide. Ever since the company launched Axon 2 AI-based advertising technology in Q2 2023, it has seen phenomenal growth and attributes its growth to AI. According to the firm, it is changing its model to use an EBITDA multiple of times 30, compared to the previous 17.5 times. A rapid reevaluation may be followed by a consolidation in the stock, and the firm would be eager to buy shares in the case the price dips.

Overall APP ranks 8th on our list of the AI stocks that should not be ignored. While we acknowledge the potential of APP as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than APP but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.

Disclosure: None. This article is originally published at Insider Monkey.

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 70%.

For a ridiculously low price of just $29, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee:  If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

 

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $29.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!


No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a year later!

Penicillin Changed the World. This Drug Could Too

This Clinical-stage Biotech Company is Taking a Revolutionary Approach to Eradicating Many Respiratory Viruses Including a single drug to treat COVID, RSV, FLU and even Monkey-pox!

This is a clinical-stage, global leader in broad-spectrum antiviral nanomedicines who is developing therapeutic drugs that work safely and effectively, even against emerging variants!

A novel broad-spectrum antiviral

NV-387,  a drug that  treats RSV, COVID-19, Long COVID, Influenza, Bird Flu H5N1, and other respiratory viral infections as well as Monkey-pox, has successfully completed Phase 1 clinical trials in healthy subjects with no reported adverse events, even at the highest and repeated dosages. Remarkably, the company has been able to develop NV-387 for oral administration already, as well as for injectable and inhalation formulations to enable many modes of use. The Company is currently focused on advancing NV-387 into Phase II human clinical trials for the treatment of RSV infection.

Susceptible viruses CANNOT escape NV-387, even as they continue to evolve in the field into variants. Why? Because  no matter how much the virus changes, it continues to use the same host-side signature to bind to and cause infection in the hosts, and thus the nanoviricide would be anticipated to continue to be effective even as the virus mutates to generate variants.

Click to continue reading…